Lung Cancer Genomic Testing Market

Market Overview

The global lung cancer genomic testing market size was valued at USD 1.38 billion in 2021. It is expected to reach USD 3.01 billion by 2030, growing at a CAGR of 9% during the forecast (2022–2030).

Cancer genomic testing is a relatively new field of genetics used to diagnose various types of cancer. Cancer genomic testing is way different from genetic testing, as all of the patient's genes are examined during genomic testing. During genomic cancer testing, gene alterations or mutations are analyzed. Initially, a patient's blood sample is required for genomic cancer testing. Cancer genomic testing assists in identifying an individual patient's cancer risk or tumor behavior. The use of genomic cancer testing to detect breast and lung cancer is in demand. When a biopsy sample is observed, it is examined to see if any genetic mutations, or changes in your genes, can be linked to the type of cancer.

Patients with lung adenocarcinoma have tumors linked to specific genetic mutations. Since some chemotherapy drugs are more effective than others in treating tumors with particular mutations, molecular analysis of your tumor, also known as genomic testing, can assist in determining which therapies are most likely beneficial to you. Non-small cell lung cancer patients are now routinely subjected to genetic testing as part of the diagnosis and staging process.

Market Dynamics

The Surge in the Number of Cancer Patients Worldwide to Favor Market Growth

It is expected that the increasing prevalence of breast and lung cancer will be the critical driver of growth in the market for genomic cancer testing during the forecast period. The rise of cancer awareness campaigns by non-governmental organizations (NGOs) contributes to expanding the market for genomic cancer testing. The development of novel cancer genomic testing techniques is receiving a dominant emphasis from major manufacturers. Increasing emphasis on research and development of lung cancer diagnostic and screening tests is another significant factor driving the market expansion.

Market Restraining Factors

Lack of Awareness to Restrict Market Growth

Screening is expensive for most people, especially those in the lower socioeconomic brackets. It's also expected that a lack of radiologists in developing and impoverished countries will limit the number of screening tests. The abovementioned issues impede the adoption of lung screening technologies, and it is anticipated that this will remain the case in the future.

Key Market Opportunities

Development of Healthcare Systems to Spur Market Opportunities

The development of healthcare structures in the direction of precision diagnostics and precision medicinal drugs will force the adoption of lung most cancer genomic testing. It can make it easier to make organizational treatment decisions and improve the overall quality of healthcare outcomes. The growing number of recommendations made by international oncology societies regarding the use of genomic testing for the analysis of lung cancers has opened many opportunities in the global market.

Regional Analysis

The global lung cancer genomic testing market is divided into North America, Europe, Latin America, and Asia-Pacific.

North America will likely dominate the global lung cancer genomic testing market, generating the most revenue. This is due to the United States abundance of research and product and service companies. Additionally, funding for research, funding advances in research, and collaboration between esteemed institutions contribute to market expansion. The Asia-Pacific region is expected to dominate the market. This is due to developments in DNA sequencing technology, an increase in life science research, and the entry of new market participants.

Segmental Analysis

The global lung cancer genomic testing market is segmented by type, technology, sample type, panel type, and end-user.

On the Basis of Type

Based on type, the global market is segmented into products and services. The services segment of the global lung cancer genomic testing market is anticipated to dominate. This is due to the easy availability, accessibility, and adaptability of LDTs and their lower cost compared to the IVD-dominated market for the product.

On the Basis of Technology

Based on technology, the global market is bifurcated into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Fluorescence in Situ Hybridization. The global lung cancer genomic testing market is anticipated to be dominated by polymerase chain reaction (PCR). This is due to the overall cost-effectiveness and high sensitivity of the PCR-based genomic test for detecting lung cancer mutations that cause disease.

On the Basis of Sampling Type

Based on sampling type, the global market is segmented into Tissue biopsy and Liquid biopsy. The market is anticipated to be dominated by tissue biopsy sample types due to the standard healthcare practice of obtaining a lung tissue biopsy for lung cancer diagnosis, which is then utilized for genomic testing.

On the Basis of Panel

Based on panel, the global market is divided into Multi-Gene and Single-Gene panels. Multi-gene panels are expected to dominate the global lung cancer genomic testing market. This is due to standard healthcare practice and the familiarity of healthcare professionals with the extraction of lung tissue biopsies for lung cancer diagnosis, which are subsequently utilized for lung cancer genomic testing.

On the Basis of End-User

Based on end-user, the global market is segmented into Research organizations, Hospitals/Clinics, and Diagnostic Laboratories. The global lung cancer genomic testing market is predicted to be dominated by research organizations. This is due to the large number of clinical research and academic institutions that utilize lung cancer genomic testing for drug development, companion diagnostic development, and patient enrollment in clinical trials.

Recent Developments

• June 2022- Tempus tied up Eli Lilly collab to bring free genomic testing to lung cancer patients.
• May 2022- Roche partnered with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure.